Crossmatching and issuing blood
16 min
- Choose an immediate-spin or antiglobulin crossmatch from the patient's antibody history
- Determine eligibility for the validated electronic-crossmatch pathway
- Verify a component at issue and state any testing still incomplete
- Read column and solid-phase results using platform-specific endpoints
Try first
Get the idea
Which crossmatch
The crossmatch tests the recipient's plasma against the red cells of the unit to be given.1,2 Its method follows the antibody screen and the record:1,3
- Screen nonreactive and no history of a clinically significant antibody. An immediate-spin crossmatch or a validated electronic crossmatch detects ABO incompatibility.
- A current or past clinically significant antibody. Antigen-negative units are crossmatched through the antiglobulin phase.
Immediate spin reads right after centrifugation at room temperature. An IgG antibody against a donor antigen needs incubation and antiglobulin reagent to show, so an immediate-spin crossmatch can look compatible and miss it.1
The electronic crossmatch
In an electronic crossmatch, a validated computer system confirms ABO compatibility without mixing plasma and cells. FDA guidance expects all of these:4
- The unit's ABO and D confirmed and entered in the system.
- The recipient's ABO and D determined twice, once on the current specimen and once more, preferably from a prior record or a separately collected specimen.
- A nonreactive current antibody screen and no history of a clinically significant antibody.
- No unresolved ABO discrepancy.
A patient who fails any of these gets a serologic crossmatch.3,4
At issue
The person issuing a unit checks the recipient's two identifiers, the donation identification number, the component, the compatibility interpretation, special requirements and the expiration. The unit is inspected for abnormal color, clots and leaks.1,3 A mismatch stops the issue until it is resolved. Units released in a life-threatening emergency before testing is complete go out under the emergency-release procedure, with a physician's signed justification. The record states which testing is incomplete, and the testing is finished promptly.2,3
Reading the platform
Each platform shows a reaction its own way.5,6
| Method | Positive | Negative |
|---|---|---|
| Tube | Agglutination or hemolysis | Cells disperse evenly |
| Column agglutination | Agglutinates trapped at the top of the gel or through it | A compact pellet at the bottom |
| Solid phase, Protein A format | A smooth layer of cells across the well | A compact button in the center |
In a column, a mixed-field reaction shows agglutinated cells in the gel and a pellet at the bottom.5
References
- Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026.
- Compatibility testing, 21 CFR §606.151 (2026). Accessed September 27, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-606/subpart-C/section-606.151
- Association for the Advancement of Blood & Biotherapies. Fundamental Standards for Blood Collection and Transfusion. 2nd ed. AABB; 2025. Accessed September 27, 2026. https://www.aabb.org/docs/default-source/default-document-library/standards/fundamental-standards-for-blood-collection-and-transfusion-2nd-ed.pdf?sfvrsn=caa34314_3
- US Food and Drug Administration. Computer Crossmatch: Computerized Analysis of the Compatibility Between the Donor's Cell Type and the Recipient's Serum or Plasma Type. Guidance for Industry. April 2011. Accessed September 27, 2026. https://www.fda.gov/media/80857/download
- Diagnostic Grifols, SA. DG Gel 8 Cards Instructions for Use. US Food and Drug Administration. Accessed September 27, 2026. https://www.fda.gov/media/188548/download
- Bio-Rad Medical Diagnostics GmbH. Solidscreen II Microplate for Solid Phase Antiglobulin Tests With TANGO Instruments Instructions for Use. US Food and Drug Administration. Accessed September 27, 2026. https://www.fda.gov/media/124013/download
Watch one
A man is scheduled for hip surgery, and the surgeon requests 2 units of red cells.
- Today's specimen types group A, D-positive. The antibody screen is nonreactive.
- The laboratory information system holds a group A, D-positive result from a specimen collected in March 2025, and no antibody history.
- The electronic crossmatch system is validated, and the group A units in stock had their ABO and D confirmed on receipt.
Can his units be issued by electronic crossmatch?
- Check identity first. The specimen label and the request carry the same two identifiers.
The electronic pathway trusts the records, so a specimen from the wrong patient defeats it.
- Compare the two ABO and D results. Today's group A, D-positive agrees with the March 2025 record.
A second determination guards against a specimen drawn from the wrong patient.
- Read today's screen. It is nonreactive.
A reactive screen needs antibody identification and a serologic crossmatch.
- Check the antibody history. There is none.
An antibody below detection today can still return after exposure.
- Check the units and the system. The unit ABO and D were confirmed, and the system is validated.
The computer can only confirm compatibility from confirmed unit data.
Your turn
Use it
- Dmitri Volkov, 29, a bike courier (MRN 7719026), arrives after a crash, bleeding heavily. The trauma physician orders 4 units of red cells at once.
- A specimen is drawn and sent before the first unit is hung.
- The blood bank issues 4 group O, D-negative units under emergency release.
- Forty minutes later his specimen types group A, D-positive.
- His antibody screen by column agglutination: screening cell I leaves a compact pellet at the bottom of the gel. Screening cell II leaves a band of agglutinates at the top.
The clue that settled this case is the band at the top of the gel for cell II. It showed an antibody that the emergency units were never tested against. His record had to say that testing was incomplete, and every unit from now on needs antigen-negative selection and an antiglobulin crossmatch.
Results
- Choose an immediate-spin or antiglobulin crossmatch from the patient's antibody history
- Determine eligibility for the validated electronic-crossmatch pathway
- Verify a component at issue and state any testing still incomplete
- Read column and solid-phase results using platform-specific endpoints
To review
6 questions from this step will come back in Review.
Next step: Hemolytic disease of the fetus and newbornReview nowOpen the part
Keep
Sources checked
The rest of this step
A short briefing, a demonstration at the bench, 3 practice problems and a short case.
A free account opens the rest and keeps your progress.